We are live on ! Find out more
GRTX

Galera Therapeutics, Inc. Common Stock
GRTX

Delisted

GRTX was delisted on the 3rd of June, 2024.

Back to rankings

33 hedge funds and large institutions have $18.1M invested in Galera Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more capital invested

Capital invested by funds: $13.7M → $18.1M (+$4.42M)

15% less funds holding

Funds holding: 39 → 33 (-6)

55% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 11

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
33
Holders Change
-6
Holders Change %
-15.38%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
11
Closed
8
Calls
$446K
Puts
–
Net Calls
+$446K
Net Calls Change
+$83K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$122K
2
Northern Trust
Northern Trust
Illinois
+$15.7K
3
TRCT
Tower Research Capital (TRC)
New York
+$14.5K
4
Group One Trading
Group One Trading
Illinois
+$1.21K
5
Citadel Advisors
Citadel Advisors
Florida
+$455

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$120K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$52K
3
CM
Crestline Management
Texas
-$45K
4
Two Sigma Investments
Two Sigma Investments
New York
-$30.7K
5
Millennium Management
Millennium Management
New York
-$24K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$5.37M – – –
NHAS
2
Novo Holdings A/S
Denmark
$4.28M – – –
Blackstone Inc
3
Blackstone Inc
New York
$2.92M – – –
TCM
4
Tekla Capital Management
Massachusetts
$1.56M – – –
NFGH
5
Nan Fung Group Holdings
Hong Kong
$1.07M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$755K -$2.8K -1,978 -0.5%
BlackRock
7
BlackRock
New York
$543K -$3.43K -2,429 -0.8%
BCM
8
Bridgeway Capital Management
Texas
$325K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$288K +$122K +86,287 +109%
Renaissance Technologies
10
Renaissance Technologies
New York
$275K -$120K -84,584 -35%
Ensign Peak Advisors
11
Ensign Peak Advisors
Utah
$264K – – –
Two Sigma Investments
12
Two Sigma Investments
New York
$64K -$30.7K -21,686 -37%
BC
13
BIT Capital
Germany
$52.2K – – –
Northern Trust
14
Northern Trust
Illinois
$51K +$15.7K +11,091 +61%
State Street
15
State Street
Massachusetts
$50K – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$45K -$5.94K -4,202 -14%
RJFSA
17
Raymond James Financial Services Advisors
Florida
$39K – – –
Citadel Advisors
18
Citadel Advisors
Florida
$28K +$455 +322 +2%
SFI
19
Susquehanna Fundamental Investments
Pennsylvania
$26K +$21.2K +15,000 New
Two Sigma Advisers
20
Two Sigma Advisers
New York
$25K -$52K -36,800 -72%
HSBC Holdings
21
HSBC Holdings
United Kingdom
$21K -$779 -551 -4%
Goldman Sachs
22
Goldman Sachs
New York
$20K -$257 -182 -2%
TRCT
23
Tower Research Capital (TRC)
New York
$18K +$14.5K +10,232 New
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$16K +$416 +294 +3%
TWA
25
TCI Wealth Advisors
Arizona
$11K – – –
1
2

GRTX Hedge Fund Activity: Q3 2022 in Review

33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q3 2022, worth a combined $18.1M — up 32% from $13.7M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GRTX and 3 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 5 added.

The largest buyer was Geode Capital Management, adding an estimated $122K. The largest seller was Renaissance Technologies, cutting an estimated $120K.

  • 33 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q3 2022, down from 39 in Q2 2022.
  • Funds reported $18.1M of Galera Therapeutics, Inc. Common Stock stock for Q3 2022, up 32% quarter-over-quarter.
  • 3 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -5 holders.
  • The largest Galera Therapeutics, Inc. Common Stock buyer in Q3 2022 was Geode Capital Management, an estimated $122K added.
  • The largest Galera Therapeutics, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $120K sold.

Based on aggregated 13F filings for Q3 2022.